Background: Lung-protective ventilation has been widely adopted for the management of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Consequently, ventilator associated lung injury and mortality have decreased. It is unknown if this ventilation strategy changes the prognostic value of previously identified demographic and pulmonary predictors of mortality, such as respiratory compliance and the arterial oxygen tension-to-inspired oxygen fraction ratio (PaO 2 /FiO 2 ).
INTRODUCTION
Despite advances in our understanding of the pathophysiology and treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), the mortality remains high, approximately 30-60% of patients die before hospital discharge (1) (2) (3) . Lung-protective ventilation, a strategy that targets lower tidal volumes (V T ) and limits plateau pressure (P plat ,) to less than 30 cm water is the only clinical intervention that has shown a mortality benefit in large randomized trials (4, 5) .
Observational studies done before widespread application of lung-protective ventilation identified demographic, pulmonary specific and clinical variables that predict mortality in ALI/ARDS (2, 3, (6) (7) (8) (9) . These included age, severe acute physiology score (SAPS II), acute physiology and chronic health evaluation (APACHE II) score, cirrhosis, immunosuppression and pulmonary specific variables including the arterial oxygen tension-to-fraction of inspired oxygen (PaO 2 /FiO 2 ) ratio (9) , respiratory system compliance (Crs) (3) and oxygenation index (OI) (7) . To our knowledge, no large study of mortality predictors has been conducted since the implementation of the lungprotective ventilation. Thus, we conducted a retrospective study of these variables to identify early predictors of mortality in ALI/ARDS after adoption of lung-protective ventilation. We hypothesized that this ventilation strategy may attenuate the predictive value of previously identified pulmonary specific measures.
METHODS

Subjects
We studied patients in both medical and surgical intensive care units identified prospectively as a part of ongoing clinical trials of ALI/ARDS between July 1 st 2002 and June 30 th 2003. The study was done at the University of California Moffitt-Long Hospital, a tertiary university referral center, and at San Francisco General Hospital, a large, inner-city hospital and Level 1 trauma center. Retrospective data collection was approved by the institutional review board of the University of California, San Francisco and given the retrospective nature of this study, the requirement for written informed consent was waived. Patients were 18 years of age or older, had received mechanical ventilation and met the North American-European consensus conference definition for ALI/ARDS (10) . No exclusion criteria were used. Ventilator management was at the discretion of the critical care team. However, both hospitals had implemented the lungprotective ventilation protocol of the ARDS Net trial.
Data Collection
The plan for data collection and the data analysis strategy were defined prospectively, before review of the medical records began. Data were recorded at a daily reference time between 0600 and 1000. Arterial blood gases (ABG) used to calculate the PaO 2 /FiO 2 , were drawn during this reference period. It is the policy of the respiratory care departments that ABG are not obtained within 20 minutes of suctioning and recruitment maneuvers are not standard treatment in our hospital system and were unlikely to confound the ABG measurements. A reference quasi-static respiratory compliance (Crs) was found to reflect average daily Crs in a sub-set of subjects (11) .
Clinical data were abstracted from the medical record for up to 7 days or until death or extubation, whichever occurred first. These data included the etiology of ALI/ARDS, coexisting medical illnesses, use of glucocorticoids, or other causes of immunosuppression, fluid intake/output and balance, vital signs and chest radiographic findings. The clinical disorder associated with ALI/ARDS was considered primary if the cause was pneumonia, aspiration, direct lung trauma or inhalational injury. All other causes were considered secondary. Of the 149 patients included in the multivariate logistic regression analysis, 22 patients had partially missing data.
Laboratory data included electrolytes, blood urea nitrogen, creatinine, white blood cell count and hematocrit. Mechanical ventilation variables included ABG, peak inspiratory pressure, plateau pressure (P plat ), positive end-expiratory pressure (PEEP), mean airway pressure (Paw), tidal volume (V T ) both in ml and ml/kg predicted body weight (PBW), respiratory frequency (f) and minute ventilation ( (9) . Higher values of OI indicate poorer oxygenation. For patients with trauma-induced ALI/ARDS the Injury Severity Score (15) also was determined.
Statistical Analysis
Death prior to hospital discharge was the primary outcome variable in this study. Patients were followed until death or discharge from the hospital. Patients were categorized as survivors or non-survivors and the variables enumerated above were compared using bivariate analysis. Continuous normally distributed variables were compared using a Student's t-test and categorical variables were compared using a chisquared test. Select variables that were statistically significant, or of a priori clinical significance, were then introduced into a forward, stepwise, logistic-regression model. SAS computer software (SAS Institute, Cary, N.C.) was used for statistical analysis. All interval data are presented as mean (SD). The goodness-of-fit of the logistic-regression model was assessed with the Hosmer-Lemeshow test. Standard regression diagnostics and goodness-of-fit testing indicated that the logistic regression models were adequate. Results were considered to be statistically significant if p < 0.05.
RESULTS
Between July 1 st 2002 and June 30 th 2003, 149 patients with ALI/ARDS were identified at the 2 hospitals and their data were incorporated into this study ( Table 1) . Patients with ALI/ARDS had moderately severe lung injury characterized by a low Crs and marked impairment in oxygenation (average PaO 2 /FiO 2 19.2 kPa). On the day of ALI/ARDS diagnosis, patients were ventilated with an average (SD) V T of 7.6 (2.1) ml/kg PBW that subsequently decreased to 7.0 (2.1) ml/kg PBW on day two, 6.8 (1.8) ml/kg PBW on day three and 6.6 (1.4) ml/kg PBW on day four.
ALI/ARDS was the result of direct pulmonary injury in 48% of patients, while 52% had an indirect or extrapulmonary cause. At enrollment 19% of patients had a PaO 2 /FiO 2 between 27-41 kPa (200-300 mmHg) and 81% had a PaO 2 /FiO 2 <27 kPa (200 mmHg). All but one patient initially diagnosed with ALI developed ARDS (PaO 2 /FiO 2 <27 kPa) within 48 hours (SD) . AIDS, acquired immunodeficiency syndrome; ALI, acute lung injury; ARDS, acute respiratory distress syndrome; APACHE, acute physiology and chronic health evaluation; Crs, respiratory system compliance; f, respiratory frequency; FiO 2 , inspired oxygen fraction; HIV, human immunodeficiency virus; LIS, lung injury score; N, number; PaO 2 , arterial oxygen partial pressure; PBW, predicted body weight; PEEP, positive end-expiratory pressure; OI, oxygenation index; SD, standard deviation; TRALI, transfusion-related lung injury; V T , tidal volume.
The overall hospital mortality in our cohort of patients with ALI/ARDS was 41% (61/149; 95% CI 33%, 49%), which was higher, but not significantly different from the mortality predicted by APACHE II (36%) and SAPS II (33%). Most patients had a variety of chronic comorbid conditions: 26% were immunosuppresed and 15% had cirrhosis. Patients originally diagnosed with ALI had a lower mortality compared to patients with ARDS (31% vs. 44%), however, this difference was not statistically significant (p = 0.21). There was no statistical difference in mortality between patients with a primary or secondary cause of ALI/ARDS. Although women accounted for only 34% of study subjects (50/149), there was a suggestion of increased mortality when compared to men: 51% (25/49) vs. 36% (36/99) respectively (p = 0.06). Of note, on entry into the study, women had a higher average APACHE II score than men (22 vs. 18, p<0.01). Non-survivors had a lower PaO 2 /FiO 2 and arterial pH, a more negative base deficit and a higher OI ( Table 2) . In the bivariate analysis, 17 variables were significantly correlated with the mortality, including increased age, cirrhosis, higher APACHE II, SAPS II (Table 2) .
Pulmonary variables correlated with death included an elevated OI (73.5 cm H 2 O/kPa vs. 111.8 cm H 2 O/kPa, p < 0.001), decreased PaO 2 /FiO 2 (both at onset of lung injury and worst value in the first 24 hours after onset of lung injury), increased FiO 2 , and lower PaO 2 . In contrast V T , f, Crs, P plat and PEEP were not statistically correlated with death. Both the presence of hemodynamic compromise (lowest systolic blood pressure, diastolic blood pressure and mean arterial pressure) and acidosis on the day of ALI/ARDS onset were significantly correlated with death. Developing ALI/ARDS from trauma predicted a better prognosis, with a mortality of only 15%.
In a multivariate logistic regression model both PaO 2 /FiO 2 and OI were predictive of death in unadjusted analysis (Table 3) . Compliance was not statistically predictive of death in unadjusted (OR = 1.22, 95% CI 0.86, 1.72) or adjusted analysis (OR = 1.23, 95% CI 0.77, 1.96) When adjusted for variables that were significant in bivariate analysis as well as other variables defined a priori (presence of chronic obstructive pulmonary disease, pneumonia, vasopressor use, and gender), PaO 2 /FiO 2 was no longer a statistically significant predictor of death (OR = 1.30, 95% CI 0.83, 2.04). In contrast, OI remained a robust predictor in adjusted analysis (OR =1.85, 95%, CI 1.14, 3.01). We also carried out multivariate logistic regression using SAPS II instead of APACHE II. Overall, the results were similar, OI was still a significant predictor of death in multivariate adjusted analysis (OR = 2.07, 95% CI 1.25, 3.22), but PaO 2 /FiO 2 was not (OR = 1.32, 95% CI 0.84, 2.06). 
DISCUSSION
In this retrospective observational study we aimed to identify early predictors of mortality in patients managed with lung-protective ventilation. In particular, we hoped to determine if Crs would still be predictive of mortality, as we found during traditional V T (10 ml/kg) ventilation in the late 1990's (3). Our primary finding was that OI, which relates severity of oxygenation impairment (PaO 2 ) to the intensity of mechanical ventilation (FiO 2 and mean airway pressure) was a predictor of death, even in an adjusted multivariate analysis.
Over the past 20 years several studies have reported that mortality from ALI/ARDS has decreased (16) (17) (18) (19) (20) , while the only therapy shown to have a mortality benefit is lung-protective ventilation (4) . Likewise, observational studies of ALI/ARDS done in the University of California San Francisco hospital system over the last 15 years have also shown a decline in mortality. In the early 1990's Doyle et al. (2) reported hospital mortality of 58% for patients with ALI/ARDS, whereas by the late 1990's Nuckton et al. (3) found that mortality in patients with ARDS alone was 42%. In this study of patients with ALI/ARDS, mortality was 41%.
The average V T on the first day of ALI/ARDS was 7.6 ml/kg PBW and decreased to 6.6 ml/kg PBW by day 4. This level was higher than the V T levels achieved during the ARDS Net study. In another observational study where the ARDS Net protocol was more strictly adhered to, as evidenced by an average V T of 6.2 ml/kg PBW that was maintained over the first week of ALI/ARDS, hospital mortality was 32% despite the presence of some of the same co-morbid conditions (21) . This finding suggests the possibility that the relatively higher mortality, despite the intention to use lung-protective ventilation, may be due to delayed recognition of ARDS or less rigorous adherence to the ARDS Net goal of a V T of 6 ml/kg PBW.
In general, non-pulmonary variables identified as predictors of mortality in studies performed prior to lung-protective ventilation were predictive of death in our study as well. These variables included age, APACHE II, SAPS II, cirrhosis and pH. (2, 3, 7) In contrast, many of the pulmonary-specific variables identified in previous studies, including Crs (3), P plat (22) and V T (3), were not significantly associated with death in our study. Limiting V T and P plat with lung-protective ventilation likely attenuates early alveolar volutrauma, which has been shown in animal models to have early effects on lung vascular permeability and thus compliance (22) . It may be that the predictive value of Crs observed in the study by Nuckton (3) reflected an injurious ventilation strategy and that lung-protective ventilation alleviates this early ventilator associated lung injury.
The value of PaO 2 /FiO 2 as an early predictor of death in ALI/ARDS is uncertain. Bone et al. (9) observed that although PaO 2 /FiO 2 was not different at onset of ARDS, survivors were characterized by a steady increase in PaO 2 /FiO 2 over the first week of conventional therapy. Likewise, in a recent review of 13 large observational trials Ware (23) found that PaO 2 /FiO 2 at the onset of ALI/ARDS did not predict clinical outcome, but a persistently low PaO 2 /FiO 2 was associated with worse outcomes and may be a marker of failure to respond to conventional therapy.
In contrast to the PaO 2 /FiO 2, OI was a robust predictor of mortality, even in the adjusted analysis. This finding supports the results of some prior investigators, although most large observational studies have not measured or reported OI (3, 7) . OI may be a better predictor of death than PaO 2 /FiO 2 because it accounts for changes in mean airway pressure as well as FiO 2 . OI has received more attention in the pediatric literature where Trachsel et al (24) found that OI, measured at any time during hospitalization, was the best pulmonary predictor of death in a group of pediatric patients with acute hypoxic respiratory failure. In addition, OI was identified as the best bedside surrogate for intrapulmonary shunt, the primary pathophysiologic derangement of ARDS (25) (26) .
The most recent AECC definition discriminates ALI from ARDS based on the level of the PaO 2 /FiO 2 .(10). The utility of this distinction in predicting morbidity and mortality and in guiding clinical decision making is uncertain. We found no statistical difference in mortality between patients originally diagnosed with ALI and those diagnosed with ARDS. In addition, we found that 97% (28/29) of patients originally diagnosed with ALI eventually develop ARDS. A recent multicenter European study involving 463 patients with ALI or ARDS (27) found that 54% of patients initially diagnosed with ALI eventually progress to ARDS. Furthermore, patients that progressed to ARDS (PaO 2 /FiO 2 ≤ 27 kPa) had a significantly higher mortality than those who did not. In addition, several other recent studies found no difference in mortality between patients with ALI or ARDS at initial diagnosis (2, 16) . Likewise, a recent study (28) with 1113 ALI/ARDS patients reported that there was no statistically significant mortality difference between patients presenting with ALI (38.5%) or ARDS (41.1%). However, the subset of patients who did not progress to a PaO 2 /FiO 2 < 27 by day 3 or 7 had a statistically lower mortality of 29%.
The AECC definition of ALI/ARDS was an important step toward standardizing a heterogeneous group of patient with lung injury. However, as discussed above, the separation of patient into ALI and ARDS may be of limited prognostic and therapeutic utility. The variability in outcomes of patients with a PaO 2 /FiO 2 < 41 kPa may be in large part due to differences in the timing of PaO 2 measurements and the relationship of this measurement to the level of PEEP. Estenssoro et al (29) There are some limitations of our study. The enrollment of patients was carried out at only two study centers, although one was a university tertiary care hospital and the other a city-county medical center. This study included 149 patients, which was large enough to identify statistical differences for several pulmonary and non-pulmonary variables, however the statistical power was not sufficient to detect differences between subsets of patients. In particular our analysis of progression from ALI to ARDS may be limited by small sample size. In addition, power may have been inadequate to detect the group.bmj.com on August 28, 2017 -Published by http://thorax.bmj.com/ Downloaded from impact of PaO 2 /FiO 2 and Crs. Moreover, many patients in this study did not achieve the lung-protective ventilation goal of a V T of 6 ml/kg. Tidal volumes were, however, uniformly lower compared with studies performed before the era of lung-protective ventilation, and they were progressively reduced over the first 4 days after the diagnosis of ALI/ARDS. Lastly, there was a small amount of missing data in our database, no more than 10 patients had missing data for bivariate analysis and 22 patients had partially missing data in the multivariate model. In summary, we conducted a study of early predictors of mortality in patients with ALI/ARDS after widespread adoption of lung-protective ventilation. We found that demographic and laboratory variables identified in prior studies, including age, APACHE II, cirrhosis and pH are still predictive of death. In contrast, several pulmonary specific variables identified in previous studies, including Crs, P plat and V T were not predictive of death. Although PaO 2 /FiO 2 was predictive of death in bivariate analysis, it was not statistically predictive in multivariate adjusted analysis. Importantly, we found that OI was the best bedside pulmonary predictor of mortality, and its predictive ability was sustained in multivariate analysis. Oxygenation index may be superior to PaO 2 /FiO 2 in predicting mortality because it integrates the important relationship between airway pressure and oxygenation into a single variable. Based on these results, OI may be a useful marker to identify subsets of patients with a poorer prognosis who might benefit from experimental therapies for ALI/ARDS. 
